Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693915 | 0.90 | MAP2K1 (0.71) | MAP2K1MAP2K2 | |
| SCHEMBL13147907 | 0.89 | MAP2K1 (0.72) | MAP2K1MAP2K2 | |
| SCHEMBL694244 | 0.86 | MAP2K1 (0.53) | MAP2K1MAP2K2 | |
| SCHEMBL13613786 | 0.86 | MAP2K1 (0.53) | MAP2K1MAP2K2 | |
| SCHEMBL697785 | 0.85 | MAP2K1 (0.76) | MAP2K1MAP2K2 | |
| SCHEMBL697699 | 0.84 | MAP2K1 (0.52) | MAP2K1MAP2K2 | |
| SCHEMBL695265 | 0.84 | MAP2K1 (0.67) | MAP2K1MAP2K2 | |
| SCHEMBL696855 | 0.84 | MAP2K1 (0.70) | MAP2K1MAP2K2 | |
| SCHEMBL697510 | 0.84 | MAP2K1 (0.53) | MAP2K1 | |
| SCHEMBL13148458 | 0.83 | MAP2K1 (0.50) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421612-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | Novartis AG (CH) | 2012-02-29 | — | — | EP | claimed |
| WO-2010121646-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | NOVARTIS AG (CH) | 2010-10-28 | — | — | WO | claimed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | claimed |
| EP-2227469-B9 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-09-10 | — | — | EP | disclosed |
| EP-2227469-B9 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-09-10 | — | — | EP | disclosed |
| EP-2227469-B1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-01-08 | — | — | EP | disclosed |
| EP-2227469-B1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-01-08 | — | — | EP | disclosed |
| EP-2421612-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | Novartis AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-8022057-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022057-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022057-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-20 | — | — | US | disclosed |
| EP-2227469-A1 | MAPK/ERK KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-09-15 | — | — | EP | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| WO-2009064675-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064675-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-22 | — | — | WO | disclosed |
| US-20090124595-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-14 | — | — | US | disclosed |
| US-20090124595-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-14 | — | — | US | disclosed |
| US-20090124595-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124595-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | MAP2K1 46/4885MAP2K2 43/4885 |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NRAS, BRAF, MAP3K1 | MAP2K1 48/4885MAP2K2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.